ZHIXIONG WANG1,2, NA RISU2, JIAYU FU2, HUI LIU3, GUOMIN ZHOU3, QIAN LIU3, YAN ZOU4, JIAXING TANG4, LONG LI4, XUEKAI ZHU4,*
BIOCELL, Vol.45, No.1, pp. 157-165, 2021, DOI:10.32604/biocell.2021.010261
- 26 January 2021
Abstract Chimeric antigen receptor (CAR) T-cell therapy is mostly limited to hematological malignancies and has a poor
effect on solid tumors. CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as
pomalidomide, so the use of pomalidomide may improve the effect of CAR T cells on solid tumors. In this study, CD133-
or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells
in vitro. We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T More >
Login
Register
